Moreover, LILRB4 expression has been correlated with a trend in increased responsiveness to hypomethylating agent (HMA) therapy in CMML and MDS, although the sample size was too small to demonstrate statistical significance [19]. Here, LILRB4 is linked to myelodysplastic syndrome.